Summary

Sinusitis Treatment Market – Scope of Report
TMR’s report on the global sinusitis treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global sinusitis treatment market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global sinusitis treatment market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the sinusitis treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global sinusitis treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global sinusitis treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global sinusitis treatment market.

The report delves into the competitive landscape of the global sinusitis treatment market. Key players operating in the global sinusitis treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global sinusitis treatment market profiled in this report.

Key Questions Answered in Global sinusitis treatment Market Report
• What is the sales/revenue generated by sinusitis treatment across all regions during the forecast period?
• What are the opportunities in the global sinusitis treatment market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Sinusitis Treatment Market – Research Objectives and Research Approach
The comprehensive report on the global sinusitis treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global sinusitis treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global sinusitis treatment market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Sinusitis Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Disease Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Sinusitis Treatment Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Disease Type/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Sinusitis Treatment Market Analysis and Forecast, by Disease Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Disease Type, 2017–2031
6.3.1. Acute Sinusitis
6.3.2. Sub-acute Sinusitis
6.3.3. Chronic Sinusitis
6.4. Market Attractiveness, by Disease Type
7. Global Sinusitis Treatment Market Analysis and Forecast, by Treatment
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Treatment, 2017–2031
7.3.1. Analgesics
7.3.2. Antibiotics
7.3.2.1. Cephalosporin
7.3.2.2. Macrolide
7.3.2.3. Penicillin
7.3.3. Antihistamines
7.3.4. Surgery
7.3.4.1. Endoscopy
7.3.4.2. Balloon Sinuplasty
7.3.5. Corticosteroids
7.3.6. Sulfonamides
7.3.7. Quinolones
7.4. Market Attractiveness, by Treatment
8. Global Sinusitis Treatment Market Analysis and Forecast, by Route of Administration
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Route of Administration, 2017–2031
8.3.1. Topical
8.3.2. Nasal
8.3.3. Oral
8.3.4. Injectable
8.4. Market Attractiveness, by Route of Administration
9. Global Sinusitis Treatment Market Analysis and Forecast, by Distribution Channel
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Distribution Channel, 2017–2031
9.3.1. Online Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Hospital Pharmacies
9.4. Market Attractiveness, by Distribution Channel
10. Global Sinusitis Treatment Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017–2031
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America Sinusitis Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Disease Type, 2017–2031
11.2.1. Acute Sinusitis
11.2.2. Sub-acute Sinusitis
11.2.3. Chronic Sinusitis
11.3. Market Attractiveness, by Disease Type
11.4. Market Value Forecast, by Treatment, 2017–2031
11.4.1. Analgesics
11.4.2. Antibiotics
11.4.2.1. Cephalosporin
11.4.2.2. Macrolide
11.4.2.3. Penicillin
11.4.3. Antihistamines
11.4.4. Surgery
11.4.4.1. Endoscopy
11.4.4.2. Balloon Sinuplasty
11.4.5. Corticosteroids
11.4.6. Sulfonamides
11.4.7. Quinolones
11.5. Market Attractiveness, by Treatment
11.6. Market Value Forecast, by Route of Administration, 2017–2031
11.6.1. Topical
11.6.2. Nasal
11.6.3. Oral
11.6.4. Injectable
11.7. Market Attractiveness, by Route of Administration
11.8. Market Value Forecast, by Distribution Channel, 2017–2031
11.8.1. Online Pharmacies
11.8.2. Retail Pharmacies
11.8.3. Hospital Pharmacies
11.9. Market Attractiveness, by Distribution Channel
11.10. Market Value Forecast, by Country/Sub-region, 2017–2031
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Disease Type
11.11.2. By Treatment
11.11.3. By Route of Administration
11.11.4. By Distribution Channel
11.11.5. By Country
12. Europe Sinusitis Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Disease Type, 2017–2031
12.2.1. Acute Sinusitis
12.2.2. Sub-acute Sinusitis
12.2.3. Chronic Sinusitis
12.3. Market Attractiveness, by Disease Type
12.4. Market Value Forecast, by Treatment, 2017–2031
12.4.1. Analgesics
12.4.2. Antibiotics
12.4.2.1. Cephalosporin
12.4.2.2. Macrolide
12.4.2.3. Penicillin
12.4.3. Antihistamines
12.4.4. Surgery
12.4.4.1. Endoscopy
12.4.4.2. Balloon Sinuplasty
12.4.5. Corticosteroids
12.4.6. Sulfonamides
12.4.7. Quinolones
12.5. Market Attractiveness, by Treatment
12.6. Market Value Forecast, by Route of Administration, 2017–2031
12.6.1. Topical
12.6.2. Nasal
12.6.3. Oral
12.6.4. Injectable
12.7. Market Attractiveness, by Route of Administration
12.8. Market Value Forecast, by Distribution Channel, 2017–2031
12.8.1. Online Pharmacies
12.8.2. Retail Pharmacies
12.8.3. Hospital Pharmacies
12.9. Market Attractiveness, by Distribution Channel
12.10. Market Value Forecast, by Country/Sub-region, 2017–2031
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Disease Type
12.11.2. By Treatment
12.11.3. By Route of Administration
12.11.4. By Distribution Channel
12.11.5. By Country/Sub-region
13. Asia Pacific Sinusitis Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Disease Type, 2017–2031
13.2.1. Acute Sinusitis
13.2.2. Sub-acute Sinusitis
13.2.3. Chronic Sinusitis
13.3. Market Attractiveness, by Disease Type
13.4. Market Value Forecast, by Treatment, 2017–2031
13.4.1. Analgesics
13.4.2. Antibiotics
13.4.2.1. Cephalosporin
13.4.2.2. Macrolide
13.4.2.3. Penicillin
13.4.3. Antihistamines
13.4.4. Surgery
13.4.4.1. Endoscopy
13.4.4.2. Balloon Sinuplasty
13.4.5. Corticosteroids
13.4.6. Sulfonamides
13.4.7. Quinolones
13.5. Market Attractiveness, by Treatment
13.6. Market Value Forecast, by Route of Administration, 2017–2031
13.6.1. Topical
13.6.2. Nasal
13.6.3. Oral
13.6.4. Injectable
13.7. Market Attractiveness, by Route of Administration
13.8. Market Value Forecast, by Distribution Channel, 2017–2031
13.8.1. Online Pharmacies
13.8.2. Retail Pharmacies
13.8.3. Hospital Pharmacies
13.9. Market Attractiveness, by Distribution Channel
13.10. Market Value Forecast, by Country/Sub-region, 2017–2031
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Disease Type
13.11.2. By Treatment
13.11.3. By Route of Administration
13.11.4. By Distribution Channel
13.11.5. By Country/Sub-region
14. Latin America Sinusitis Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Disease Type, 2017–2031
14.2.1. Acute Sinusitis
14.2.2. Sub-acute Sinusitis
14.2.3. Chronic Sinusitis
14.3. Market Attractiveness, by Disease Type
14.4. Market Value Forecast, by Treatment, 2017–2031
14.4.1. Analgesics
14.4.2. Antibiotics
14.4.2.1. Cephalosporin
14.4.2.2. Macrolide
14.4.2.3. Penicillin
14.4.3. Antihistamines
14.4.4. Surgery
14.4.4.1. Endoscopy
14.4.4.2. Balloon Sinuplasty
14.4.5. Corticosteroids
14.4.6. Sulfonamides
14.4.7. Quinolones
14.5. Market Attractiveness, by Treatment
14.6. Market Value Forecast, by Route of Administration, 2017–2031
14.6.1. Topical
14.6.2. Nasal
14.6.3. Oral
14.6.4. Injectable
14.7. Market Attractiveness, by Route of Administration
14.8. Market Value Forecast, by Distribution Channel, 2017–2031
14.8.1. Online Pharmacies
14.8.2. Retail Pharmacies
14.8.3. Hospital Pharmacies
14.9. Market Attractiveness, by Distribution Channel
14.10. Market Value Forecast, by Country/Sub-region, 2017–2031
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Disease Type
14.11.2. By Treatment
14.11.3. By Route of Administration
14.11.4. By Distribution Channel
14.11.5. By Country/Sub-region
15. Middle East & Africa Sinusitis Treatment Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Disease Type, 2017–2031
15.2.1. Acute Sinusitis
15.2.2. Sub-acute Sinusitis
15.2.3. Chronic Sinusitis
15.3. Market Attractiveness, by Disease Type
15.4. Market Value Forecast, by Treatment, 2017–2031
15.4.1. Analgesics
15.4.2. Antibiotics
15.4.2.1. Cephalosporin
15.4.2.2. Macrolide
15.4.2.3. Penicillin
15.4.3. Antihistamines
15.4.4. Surgery
15.4.4.1. Endoscopy
15.4.4.2. Balloon Sinuplasty
15.4.5. Corticosteroids
15.4.6. Sulfonamides
15.4.7. Quinolones
15.5. Market Attractiveness, by Treatment
15.6. Market Value Forecast, by Route of Administration, 2017–2031
15.6.1. Topical
15.6.2. Nasal
15.6.3. Oral
15.6.4. Injectable
15.7. Market Attractiveness, by Route of Administration
15.8. Market Value Forecast, by Distribution Channel, 2017–2031
15.8.1. Online Pharmacies
15.8.2. Retail Pharmacies
15.8.3. Hospital Pharmacies
15.9. Market Attractiveness, by Distribution Channel
15.10. Market Value Forecast, by Country/Sub-region, 2017–2031
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Disease Type
15.11.2. By Treatment
15.11.3. By Route of Administration
15.11.4. By Distribution Channel
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2022)
16.3. Company Profiles
16.3.1. Sun Pharmaceutical Industries, Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Disease Type Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Pfizer, Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Disease Type Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Disease Type Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Fresenius Kabi USA, LLC
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Disease Type Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Dr. Reddy’s Laboratories, Inc.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Disease Type Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Novartis AG
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Disease Type Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Teva Pharmaceutical Industries Ltd.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Disease Type Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Sanofi
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Disease Type Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Abbott Laboratories
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Disease Type Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Bayer AG
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Disease Type Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
16.3.11. Eli Lilly and Company
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Disease Type Portfolio
16.3.11.3. Financial Overview
16.3.11.4. SWOT Analysis
16.3.11.5. Strategic Overview
16.3.12. Bristol-Myers Squibb
16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.12.2. Disease Type Portfolio
16.3.12.3. Financial Overview
16.3.12.4. SWOT Analysis
16.3.12.5. Strategic Overview
16.3.13. Merck & Co., Inc.
16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.13.2. Disease Type Portfolio
16.3.13.3. Financial Overview
16.3.13.4. SWOT Analysis
16.3.13.5. Strategic Overview
16.3.14. AstraZeneca plc
16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.14.2. Disease Type Portfolio
16.3.14.3. Financial Overview
16.3.14.4. SWOT Analysis
16.3.14.5. Strategic Overview
16.3.15. Amneal Pharmaceuticals LLC
16.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.15.2. Disease Type Portfolio
16.3.15.3. Financial Overview
16.3.15.4. SWOT Analysis
16.3.15.5. Strategic Overview
16.3.16. GlaxoSmithKline plc
16.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.16.2. Disease Type Portfolio
16.3.16.3. Financial Overview
16.3.16.4. SWOT Analysis
16.3.16.5. Strategic Overview
16.3.17. Apotex, Inc.
16.3.17.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.17.2. Disease Type Portfolio
16.3.17.3. Financial Overview
16.3.17.4. SWOT Analysis
16.3.17.5. Strategic Overview
16.3.18. Hikma Pharmaceuticals plc
16.3.18.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.18.2. Disease Type Portfolio
16.3.18.3. Financial Overview
16.3.18.4. SWOT Analysis
16.3.18.5. Strategic Overview
16.3.19. Wockhardt
16.3.19.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.19.2. Disease Type Portfolio
16.3.19.3. Financial Overview
16.3.19.4. SWOT Analysis
16.3.19.5. Strategic Overview
16.3.20. Mylan N.V.
16.3.20.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.20.2. Disease Type Portfolio
16.3.20.3. Financial Overview
16.3.20.4. SWOT Analysis
16.3.20.5. Strategic Overview